Drug Profile
Research programme: PEPCK modulators - OSI Pharmaceuticals
Alternative Names: PEPCK modulators research programme - OSI PharmaceuticalsLatest Information Update: 11 Oct 2000
Price :
$50
*
At a glance
- Originator OSI Pharmaceuticals
- Class Small molecules
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Type 2 diabetes mellitus
Most Recent Events
- 11 Oct 2000 No-Development-Reported for Type-2 diabetes mellitus in USA (Unknown route)
- 28 May 1998 Preclinical development for Diabetes mellitus in USA (Unknown route)
- 28 May 1998 Preclinical development for Type-2 diabetes mellitus in USA (Unknown route)